This step is repeated several times to do several stimulations.

Vaccination with a vaccine composed by autologous DCs pulsed with apoptotic autologous ovarian carcinoma cells. Apoptosis is induced by UV.

refolded CD1 molecules are used to generate CD1 tetramers

Electroporation of autologous DCs electroporated with mRNA encoding CD40L, CD70, caTLR4 and one tumorantigen (gp100, Tyrosinase, Mage-C2 or Mage-A3) to produce the vaccine

CD1 molecules are refolded in vitro.

Patients with advanced prostate carcinoma are vaccinated with the DC vaccine.

Pulsing of autologous DCs with apoptotic autologous ovarian carcinoma cells.

Autologous DC are pulsed with the apoptotic allogenic prostate carcinoma cell line LNCap to produce the vaccine for patients with advanced prostate carcinoma..

Transfection of immature DCs with different constructs encoding for the oncogene Her-2/neu and as control PSA using the technology of Amaxa biosystems or an adeno virus Her-2 full length construct.

The monocytes are cultured for five days to immature DC (imDC´s).

Leukapheresis products from cancer patients is used as a starting material for monocyte enrichment by elutriation technology with ELUTRA® (Gambro).

Patients will undergo leukapheresis.

The patients will be vaccined with the DC vaccine that consists of monocyte derived DC loaded with tumor lysate generated from the excised lesion.

The primary objective of this trial is to determine toxicity and feasibility of treatment of patients with advanced melanoma with DC vaccine and adoptive transfer.

Patients will undergo surgical removal of a metastatic lesion.

Patients will undergo lymphodepletion prior to vaccination and prior to adoptive transfer of autologous T cells.

Sources for tumor antigens as well as monocytes and T cells will be isolated from the leukapheresis product by elutriation.

The T cell transfer will consist of T cells expanded by co-culture with tumor lysate loaded DC.

Generation of tumor lysate loaded DC.

The DC vaccine will consist of monocyte derived DC loaded with tumor lysate generated from the excised lesion.